Ramucirumab therapy in patients with advanced gastric cancer: discussion of a case series
- Authors: Orlova RV1, Zhukova LG2, Ganshina IP2, Yukalchuk DY.3, Ponomarenko DM3, Beliak NP4, Gordeeva OO2, Erdniev SP4, Minasyan AA5, Dashkova AA5, Sopiya ER5, Sholokhova EA5, Gurochkin AB5
-
Affiliations:
- Saint Petersburg State University
- N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
- Irkutsk Regional Oncological Dispensary
- City Clinical Oncology Dispensary
- Eli Lilly and Company
- Issue: Vol 20, No 1 (2018)
- Pages: 35-41
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27166
- ID: 27166
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
R V Orlova
Saint Petersburg State Universityд-р мед. наук, проф., зав. каф. онкологии 199034, Russian Federation, Saint Petersburg, Universitetskaia nab., d. 7/9
L G Zhukova
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: zhukova.lyudmila@rambler.ru
д-р мед. наук, и.о. зав. отд-нием химиотерапии и комбинированного лечения злокачественных опухолей 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
I P Ganshina
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federationканд. мед. наук, вед. науч. сотр. отд-ния химиотерапии и комбинированного лечения злокачественных опухолей 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
D Yu Yukalchuk
Irkutsk Regional Oncological Dispensaryканд. мед. наук, врач высшей категории 664035, Russian Federation, Irkutsk, ul. Frunze, d. 32
D M Ponomarenko
Irkutsk Regional Oncological Dispensaryканд. мед. наук, зав. химиотерапевтическим отд-нием; врач высшей категории 664035, Russian Federation, Irkutsk, ul. Frunze, d. 32
N P Beliak
City Clinical Oncology Dispensaryканд. мед. наук, врач-онколог 11-го химиотерапевтического отд-ния 198255, Russian Federation, Saint Petersburg, Prospect Veteranov, d. 56
O O Gordeeva
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federationаспирант отд-ния химиотерапии и комбинированного лечения злокачественных опухолей 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
S P Erdniev
City Clinical Oncology Dispensaryканд. мед. наук, зав. химиотерапевтическим отд-нием 198255, Russian Federation, Saint Petersburg, Prospect Veteranov, d. 56
A A Minasyan
Eli Lilly and Companyнауч. советник по клин. исследованиям 123112, Russian Federation, Moscow, Presnenskaia nab., d. 10
A A Dashkova
Eli Lilly and Companyканд. мед. наук, мед. конс. по онкологии 123112, Russian Federation, Moscow, Presnenskaia nab., d. 10
E R Sopiya
Eli Lilly and Companyканд. мед. наук, ст. мед. конс. по онкологии 123112, Russian Federation, Moscow, Presnenskaia nab., d. 10
E A Sholokhova
Eli Lilly and Company
Email: Sholokhova_evgeniya@lilly.com
ст. мед. советник по онкологии 123112, Russian Federation, Moscow, Presnenskaia nab., d. 10
A B Gurochkin
Eli Lilly and Companyканд. мед. наук, мед. дир. 123112, Russian Federation, Moscow, Presnenskaia nab., d. 10
References
- Ervik M, Lam F, Ferlay J et al. Cancer Today. Lyon, France: International Agency for Research on Cancer. Cancer Today 2016. http://gco.iarc.fr/today
- Wagner A.D, Grothe W, Haerting J et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24 (18): 2903-9.
- Spratlin J.L, Cohen R.B, Eadens M et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28 (5): 780-7.
- Tian S, Quan H, Xie C et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 2011; 102 (7): 1374-80.
- Fuchs C.S, Tomasek J, Yong C.J et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383 (9911): 31-9.
- Wilke H, Muro K, Van Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15 (11): 1224-35.
- Cyramza [product guide]: Indianapolis, IN: Eli Lilly and Company, 2016. http://www.cyramzahcp.com/img/pdf/CYRAMZA_Product_ Guide.pdf
- European Medicines Agency. Cyramza, summary of product characteristics. 2017. http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/002829/WC5001 80724.pdf
- Hamnvik O.P, Choueiri T.K, Turchin A. et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015; 121 (2): 311-9.
- Pacheco S, Norero E, Canales C et al. The Rare and Challenging Presentation of Gastric Cancer during Pregnancy: A Report of Three Cases. J Gastric Cancer 2016; 16 (4): 271-6.
- Tabernero T, Ohtsu A, Muro K et al. Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Mol Cancer Ther 2017; 16 (10): 2215-22.
- Fuchs C.S, Tabernero J, l-Batran S.E et al. A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117). J Clin Oncol 2016; 33 (4 Suppl.): TPS178.